Advanced

AJNR - American Journal of Neuroradiology

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Floeth, F. W. Articles by Weber, F. Search for Related Content PubMed PubMed Citation Articles by Floeth, F. W. Articles by Weber, F.

American Journal of Neuroradiology 22:1517-1527 (9 2001)
© 2001 American Society of Neuroradiology

ARTICLE

MR Imaging and Single-Photon Emission CT Findings after Gene Therapy for Human Glioblastoma

Frank W. Floeth^a, Albrecht Aulich^a, Karl J. Langen^a, Klaus J. Burger^a, Wolfgang J. Bock^a and Friedrich Weber^a

^a From the Departments of Neurosurgery (F.W.F., W.J.B., F.W.) and Diagnostic Radiology (A.A.), Heinrich-Heine-University, Düsseldorf; Institute of Medicine (K.J.L.), Research Center Jülich, Jülich; and Novartis Pharma GmbH (K.J.B.), Nürnberg, Germany.

BACKGROUND AND PURPOSE: Our goal was to evaluate MR imaging findings after local intracerebral gene therapy in patients with glioblastoma and differentiate postoperative contrast enhancement phenomena.

METHODS: In all, 26 patients with supratentorial single lesion glioblastoma underwent tumor resection and intracerebral injection of murine retroviral vector–producer cells for gene therapy with the herpes simplex virus type I thymidine kinase gene/ganciclovir system. Serial contrast-enhanced MR studies were obtained before treatment and postoperatively on day 1 or 2; weeks 2, 4, 9, 13, 17, 25, and 33; and every 8 weeks thereafter. Iodomethyltyrosine single-photon emission CT (IMT-SPECT) investigations also were performed in selected cases.

RESULTS: Twelve patients showed nontumorous enhancement of various intensities after treatment, arising within 18 to 72 hours and persisting at 3 to 10 months. It was characterized by a strong local enhancement up to 20 mm thick, which was initially nodular and later linear along the resection cavity wall and surrounded by massive perifocal edema. This "flare" enhancement had features that clearly differed from those of residual tumor enhancements and benign postsurgical enhancements. The IMT-SPECT investigations showed increased amino acid uptake in patients with enhancement from residual or relapsing tumor, but not in patients with flare.

CONCLUSION: After local gene therapy, a unique dynamic, transient perifocal flare enhancement can occur on MR images. IMT-SPECT may help to differentiate between tumorous and nontumorous flare enhancements in patients with enhancing tissue on MR images after gene therapy for glioblastoma.

This article has been cited by other articles:

				M. J. van den Bent, M. A. Vogelbaum, P. Y. Wen, D. R. Macdonald, and S. M. Chang End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria J. Clin. Oncol., June 20, 2009; 27(18): 2905 - 2908. [Full Text] [PDF]

				D. Pauleit, F. Floeth, L. Tellmann, K. Hamacher, H. Hautzel, H.-W. Muller, H. H. Coenen, and K.-J. Langen Comparison of O-(2-18F-Fluoroethyl)-L-Tyrosine PET and 3-123I-Iodo-{alpha}-Methyl-L-Tyrosine SPECT in Brain Tumors J. Nucl. Med., March 1, 2004; 45(3): 374 - 381. [Abstract] [Full Text]